633283-53-1

Basic information

• Product Name: tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate
• Synonyms: tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate
• CAS NO: 633283-53-1
• Molecular Formula: C₁₄H₂₀ClN₃O₂
• Molecular Weight: 298
• Mol File: 633283-53-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate(633283-53-1)
• EPA Substance Registry System: tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate(633283-53-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 633283-53-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate is used as a key intermediate in organic synthesis for the preparation of various biologically active compounds. Its unique structure and functional groups facilitate the synthesis of complex organic molecules, making it a valuable component in the development of new chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate is used as a precursor in the development of potential therapeutic agents. Its chemical properties and reactivity allow for the creation of new drug candidates with potential applications in treating various diseases and medical conditions.
Used in Medicinal Chemistry:
Tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate is utilized in medicinal chemistry as a building block for the design and synthesis of novel pharmaceutical compounds. Its presence in the molecular structure can influence the pharmacological properties of the final product, contributing to the development of more effective and targeted therapies.
Used in Drug Development:
In the field of drug development, tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate is employed as a crucial component in the synthesis of new drug candidates. Its versatility and reactivity enable the creation of a wide range of pharmaceutical compounds with diverse therapeutic applications.
Used in Chemical Research:
Tert-Butyl 4-(6-chloropyridin-3-yl)piperazine-1-carboxylate is also used in chemical research to explore its properties and potential applications. Researchers investigate its reactivity, stability, and interactions with other molecules to gain insights into its behavior and possible uses in various chemical processes.

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1169698-64-9 C₃₀H₃₇N₇O₂ 
• 1198408-35-3 6-amino-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 1374639-78-7 N,N‐dimethyl‐7‐cyclopentyl‐2‐{[5‐(4-tert-butoxycarbonylpiperazin‐1‐yl)pyridin‐2‐yl]amino}‐7H‐pyrrolo[2,3‐d]pyrimidine‐6‐carboxamide 
• 1588958-80-8 9-(3,3-dimethylcyclohexyl)-N-(5-(piperazin-1-yl)pyridin-2-yl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-amine 
• 1588958-77-3 9-((1r,4r)-4-methylcyclohexyl)-N-(5-(piperazin-1-yl)pyridin-2-yl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-amine 
• 1169692-54-9 9-(4-methylcyclohexyl)-N-(5-(1-piperazinyl)-2-pyridinyl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-amine 
• 1169692-19-6 (9-cyclohexyl-9H-pyrido[4′,3′,4,5]pyrrolo[2,3-d]pyrimidin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)amine 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

Streamlined Synthesis of Diaminopyridines by Pd-Catalyzed Ammonia Coupling with Deactivated Amino-Chloropyridines

An efficient and cost-effective two-step synthesis of diaminopyridines, fundamental building blocks of biologically active compounds, is reported. The advantages over previously reported routes include cost and wider availability of the bromo-chloropyridine starting materials and the straightforward accessibility to an extended array of diaminopyridine regioisomers. The key enabler of this synthetic strategy is the development of an unprecedented palladium-catalyzed coupling reaction of ammonia with chloropyridines deactivated by the presence of an alkylamino substituent. The coupling reaction was accomplished with very low catalyst loadings under remarkably mild reaction conditions, making the system particularly suitable for both academic and industrial applications. The utility of this methodology is exemplified by the application to the synthesis of highly relevant scaffolds, including the synthetic intermediates of the marketed drugs Ribociclib and Palbociclib.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3

We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb +) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4 mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are gem-disubstituted or spirocyclic pyridine, pyrimidine and triazine derivatives.

G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

Selective Amination of Polyhalopyridines Catalyzed by a Palladium-Xantphos Complex

(Matrix presented) Amination of 5-bromo-2-chloropyridine (1a) catalyzed by a palladium-Xantphos complex predominately gives 5-amino-2-chloropyridine product 3a in 96% isolated yield and excellent chemoselectivity (3a/4a = 97:3). Amination of 2,5-dibromopyridine (11) under the same conditions exclusively affords 2-amino-5-bromopyridine 4a.